Prophylaxis of deep vein thrombosis with fixed low-dose warfarin in patients with multiple myeloma receiving first-line combined thalidomide-dexamethasone. Hematol J 2003; 4: S251, abstract). However, others could not demonstrate a beneficial effect when using 1 mg fixed-dose warfarin, but also reported comparable VTE incidences with their control arm when changing to LMWH prophylaxis. (Zangari M, Barlogie B, Saghafifar F et al. Effect of anticoagulation on development and recurrence of deep vein thrombosis (DVT) in multiple myeloma patients treated with chemotherapy and thalidomide (Total therapy II). Hematol J 2003; 4: S248, abstract).
In conclusion, standard LMWH (nadroparine) prophylaxis during chemotherapy is safe and effective in reducing the incidence of thalidomide-associated VTE in newly diagnosed MM patients. Survivin is a member of the inhibitors of apoptosis gene family and is abundantly expressed in several cancer entities including hematopoietic malignancies but is undetectable in terminally differentiated adult tissues with only a few exceptions. 1 Survivin could be specifically recognized by the immune system and thus can be regarded as a tumor-associated antigen. 2, 3 Recently, several reports demonstrated that cytotoxic T lymphocytes (CTLs) specific for survivin-derived determinants are capable of efficiently killing leukemia targets endogenously expressing survivin. [3] [4] [5] [6] [7] In the current study, we identified a new HLA-A2-binding epitope, survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (TLPPAWQPFL) . Using the T2 cellbinding assay, we found that survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] showed comparable binding activity as the positive control peptide FluM1 58-66 (GILGFVFTL, data not shown). CTLs specific for survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] recognized and efficiently killed survivin þ primary malignant cells from patients with chronic lymphatic leukemia (CLL) and acute myeloid leukemia (AML; Figure 1a and c) without attacking HLA-A2-negative tumor cells or normal hematopoietic progenitor cells (Figure 1b and d) . Survivin 5-14 -specific CTLs only recognized and killed T2 cells pulsed with the cognate peptide but spared target cells loaded with a control peptide (survivin 95-104 ; Figure 1e ). Cold target inhibition assays and antibody blocking experiments revealed an MHC class I-restricted killing process induced by peptide-specific CD8 þ T lymphocytes (Figure 1f and g ). Survivin 5-14 -specific CTLs show a high affinity of the peptide/MHC complex, as evidenced by peptide titration assays (Figure 1h) . Furthermore, patient-derived CTLs specific for the survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] peptide are also capable of lysing autologous AML and B-CLL cells (Figure 1i) .
MC
Taken together, the present data and the previous work by the groups of Andersen [3] [4] [5] and Brossart 7 clearly demonstrate that survivin is a useful target molecule for T-cell-based peptide vaccination strategies against both AML and CLL. In a current vaccination study, this issue will be further addressed at our department. Cold target inhibitions assays (f) and antibody blocking experiments (g) document the specificity of survivin peptide-specific CTLs. Peptide titration assays were performed utilizing survivin peptide-specific CTLs against T2 cells loaded with the cognate peptide or the control peptide (HIVpol 476-484 ILKEPVHGV; see panels e and h). In one patient with CLL (CLL-01) and in another with AML (AML-02), autologous CTLs specific for survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] capable of lysing their autologous malignant targets could be generated (i).
